NDATOPICALSOLUTION
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLUPREP S is a topical antiseptic solution combining chlorhexidine gluconate and isopropyl alcohol, indicated for skin antisepsis prior to medical procedures and injections. It provides rapid broad-spectrum antimicrobial activity to reduce the risk of infection at procedural sites. The formulation leverages the synergistic effect of two well-established antimicrobial agents for enhanced efficacy.
PeakPost-LOE
Product is at peak commercial maturity with moderate competitive pressure (30%), indicating stable market demand and mature team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SOLUPREP S offers experience in mature product management and hospital/procedural market dynamics within a tier-one medical device company. The approaching LOE and peak lifecycle status makes this role best suited for professionals seeking expertise in market defense, pricing strategy, and managed transition planning.
Brand ManagerField Sales Representative
Worked on SOLUPREP S at Becton Dickinson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.